A Clinical Study Evaluating the Pharmacokinetic Characteristics and Safety of AHB-137 Injection in Participants With Mild to Moderate Liver Dysfunction and Those With Normal Liver Function.

ClinicalTrials.gov ID

NCT07600788

Lead Sponsor

Ausper Biopharma Co., Ltd.INDUSTRY

Overall Status

Recruiting

Study Type

Interventional

Phase

Phase 1

Enrollment

32Estimated

Last Update Posted

Jul 29, 2026Actual

Start Date

Jul 9, 2026Actual

Primary Completion Date

May 15, 2028Estimated

Completion Date

May 15, 2028Estimated

Official Title

A Clinical Study Evaluating the Pharmacokinetic Characteristics and Safety of AHB-137 Injection in Participants With Mild to Moderate Liver Dysfunction and Those With Normal Liver Function.

Brief Summary

A clinical study evaluating the pharmacokinetic characteristics and safety of AHB-137 injection in participants with mild to moderate liver dysfunction and those with normal liver function.

• Chronic Hepatitis B

• AHB-137 injection

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

Yes

Eligibility Criteria

Inclusion Criteria:

• Voluntarily participate in the study, sign an informed consent form before the study and be able to complete the study according to the requirements of the protocol;
• At the time of signing the informed consent form, male or female participants aged 18-65 years (including threshold values);
• Body mass index meets the criteria;
• Take effective contraceptive measures as required;
• Participants with liver function impairment need to meet certain liver function assessments;
• Participants with normal liver function should meet certain age, weight, and gender requirements to match those with liver function impairment, and should also undergo certain physical and laboratory tests.

Exclusion Criteria:

• Diagnosed or suspected liver cancer participants who have undergone liver transplantation;
• History of vasculitis or presence of signs and symptoms of potential vasculitis or laboratory tests;
• Unstable control of hypertension or diabetes, progressive nervous system disease, history of immune related extrahepatic diseases, and unstable cardiac function;
• Participants with a history of malignant tumors or undergoing malignant tumor assessment;
• Screening for participants who have undergone significant trauma or surgery within the previous 3 months, as well as those who plan to undergo surgery;
• Participants with thyroid dysfunction who are not suitable for inclusion in the study;
• Allergic or allergic constitution to AHB-137;
• Long term regular receipt of anticoagulant or antiplatelet drugs is required;
• Those who have received any antisense oligonucleotide drugs or have been treated with siRNA drugs or interferon within the 12 months prior to screening;
• Currently using or using any immunosuppressive medication within the past 3 months prior to screening, except for short-term use or the use of topical/inhaled steroids; Individuals who have used immunomodulators and cytotoxic drugs within the 6 months prior to administration;
• Those who have a history of vaccination or a plan to receive live vaccines within one month before administration, those who have used creatine containing fitness supplements 14 days before administration, and those who have used albumin 14 days before administration;
• HIV, Syphilis positive ;
• Those who are participating in another clinical trial and have not been eluted as required;
• Positive results in urine drug screening and alcohol breath screening tests during screening;
• Those who drink excessively and consume prohibited foods and beverages before administration;
• Participants who have donated blood (or lost blood) ≥ 400 ml, received whole blood, or used red blood cell suspension within the past 3 months prior to screening; Individuals with a history of needle or blood dizziness, difficulty in blood collection, or intolerance to venipuncture blood collection;
• Long term regular vigorous exercise or intense exercise within 48 hours before screening;
• Any other circumstances or conditions that the researcher deems unsuitable for the subject to participate in this study;
• Diseases that need to be excluded according to the merger plan for patients with abnormal liver function;
• The laboratory test results do not meet the requirements of the protocol;
• Participants with normal liver function who have a history of chronic liver disease or known liver or biliary abnormalities;
• Participants with normal liver function who have used traditional Chinese medicine or other systemic medications with potential liver toxicity 14 days before administration;
• Participants with normal liver function and abnormal QTcF values.

Primary Purpose

Treatment

Allocation

Non-Randomized

Interventional Model

Parallel Assignment

Masking

None (Open Label)

Lead Sponsor

Ausper Biopharma Co., Ltd.INDUSTRY

clinicaltrial@ausperbio.com057186959519

clinicaltrial@ausperbio.com057186959519

clinicaltrial@ausperbio.com057186959519

• A Study to Evaluate AHB-137 Injection in Treatment-naïve Participants With Chronic Hepatitis B

  NCT07635186

  RecruitingInterventionalPhase 2Updated Jul 29, 2026
• A Study Evaluating AHB-137 in Healthy Participants and Participants with Chronic Hepatitis B

  NCT05717686

  CompletedInterventionalPhase 1Updated Feb 14, 2025
• A Study to Evaluate the Safety and Efficacy of AHB-137 in Healthy Participants and HBeAg-negative Chronic Hepatitis B (CHB) Patients

  NCT06115993

  CompletedInterventionalPhase 1Phase 2Updated May 7, 2026
• Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB).

  NCT06550128

  Active, not recruitingInterventionalPhase 2Updated Jul 29, 2026
• A Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB)

  NCT07137910

  RecruitingInterventionalPhase 2Updated Aug 5, 2026
• A Phase I Clinical Study of AHB - 171 in Healthy Participants(HP) and Chronic Hepatitis B (CHB) Participants

  NCT07511218

  RecruitingInterventionalPhase 1Updated Jul 21, 2026